Ondansetron for diarrhea associated with neuroendocrine tumors

New England Journal of Medicine

Volumn 368, Issue 20, 2013, Pages 1947-1948

  Kiesewetter, Barbara ^a   Raderer, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CHROMOGRANIN A; OCTREOTIDE; ONDANSETRON; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN RECEPTOR;

CARCINOID SYNDROME; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; HUMAN; LETTER; MAINTENANCE THERAPY; METASTASIS POTENTIAL; NAUSEA; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEROTONIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84877783580     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1301537     Document Type: Letter

References (4)

1. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61-72.
2. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate longacting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999;17:600-6. (Pubitemid 29075248)
3. Modlin IM, Pavel M, Kidd M, Gustaffson BI. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumors. Aliment Pharmacol Ther 2010;31:169-88.
4. Wymenga ANM, de Vries EGE, Lejisma MK, Kema IP, Kleibeuker JH. Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome. Eur J Cancer 1998;34:1293-4. (Pubitemid 28342124)